Market Context — Why This Technology, Why Now

The demand for non-invasive medical procedures is surging globally, fueled by an aging demographic, increased prevalence of chronic diseases, and a push for home-based care solutions. Regulatory bodies are also encouraging safer, more patient-friendly drug administration methods. This technology directly addresses these trends by offering a pain-free, infection-risk-free alternative to injections, poised to capture a significant share of the expanding ~$65B global drug delivery market.

Key Competitive Advantages
01

Eliminates needle-related pain, fear, and infection risks, potentially reducing patient burden by ~30% and improving treatment adherence.

02

Delivers drugs to deep tissue layers with high precision, utilizing light-induced shockwaves and cavitation bubbles for ~90% intact drug delivery.

03

Establishes a robust patent foundation, having overcome two office actions and five prior art citations, ensuring strong protection for ~15 years.

Market Opportunity
Pharmaceuticals and Medical Devices
$3.5B–$35B globally (AI est.)
Innovating drug delivery methods for injectables directly enhances pharmaceutical companies' competitiveness. There is high demand for efficient and safe administration of expensive drugs, particularly biologics.
Major pharmaceutical companies focusing on biologics Medical device manufacturers specializing in drug delivery systems Contract Development and Manufacturing Organizations (CDMOs) for injectables
Home Healthcare and Self-Care
$2B–$20B globally (AI est.)
The increasing number of elderly and chronic disease patients drives urgent demand for simple, safe drug administration devices for home use. Ease of patient self-operation is a critical factor.
Home medical equipment providers Consumer health technology companies Digital health platform developers for chronic disease management
Aesthetics and Regenerative Medicine
$1.5B–$15B globally (AI est.)
Non-invasive and efficient deep tissue delivery of cosmetic ingredients and regenerative medicine cells is highly sought after. Reducing pain and downtime offers a significant competitive advantage.
Aesthetic device manufacturers Cosmeceutical companies Regenerative medicine therapy developers
IP Defensibility — Why Competitors Can't Replicate This
What This Patent Covers

This patent protects a broad scope of claims, covering the structural components and drug release mechanisms of a light-based drug delivery device. It successfully navigated two office actions against five prior art documents, establishing a robust and difficult-to-invalidate intellectual property foundation for licensees.

Competitive White Space

White space exists in developing novel drug formulations specifically optimized for light-activated release, or integrating this device with real-time diagnostic feedback systems for personalized dosing. Further IP could also be built around advanced material science for the drug supply unit to target specific tissue types.

Economic Impact
~$1.5M/year estimated medical cost reduction per facility (est.)
estimated ROI · USD · AI analysis
ROI Calculation Logic

Assuming deployment in a medical facility performing 1 million conventional injections annually: Eliminating needle disposal costs ($0.33/dose, AI est.) and reducing healthcare worker preparation/post-treatment time ($0.67/dose, AI est.) results in direct annual savings of ~$1M (AI est.). Including indirect benefits like reduced infection risk and improved patient adherence, the total economic impact could reach ~$1.5M per year (AI est.).

Speed to Market
4× faster than in-house development
Developing a similar needle-free drug delivery technology in-house from scratch would require approximately 3.5 years for fundamental research, device design, safety evaluation, and regulatory compliance. This patent provides a well-established technical foundation, detailing the specific configurations of the light source and drug supply unit, as well as the drug release mechanism. With the intent for licensing from the National Research and Development Agency, integrating this technology could reduce development time to about 1.0 year, significantly accelerating time to market.
Competitive Positioning

X: Patient Burden Reduction
Y: Deep Drug Penetration

Business Models & Applications
💡 Licensing to Medical Device Manufacturers
Provide licenses to existing medical device manufacturers for developing, manufacturing, and selling new drug release devices incorporating this technology, enabling rapid market expansion and monetization.
🤝 Joint Development with Pharmaceutical Companies
Collaborate with pharmaceutical companies to develop drug release devices specifically tailored for certain medications (e.g., biologics), enhancing the value proposition of those drugs.
💉 Direct Sales of Branded Devices
Develop and manufacture proprietary drug release devices under a private brand, selling directly to medical institutions and patients. This could position the company as a leader in high-value products.
Adjacent Application Opportunities
🐾 Veterinary Hospitals & Pet Care
Needle-Free Pet Medication Device
Administering medication to animals often causes stress for pets and burden for owners. Applying this technology to develop a needle-free device could reduce pain and fear for pets, offering new value to the ~$10B global animal health market.
🌿 Smart Agriculture
Precision Nutrient & Pesticide Delivery for Plants
This light-based drug release technology could be adapted for non-contact, high-precision delivery of nutrients or pesticides to specific plant parts or deep tissues. This has the potential to reduce pesticide use by ~20% and increase crop yields.
💄 Cosmetics & Aesthetics
Deep Penetration Device for Cosmetic Actives
The technology could be repurposed for non-invasive, deep penetration of serums and active ingredients into the skin. By eliminating needles, it reduces skin burden and could offer more effective skincare solutions for the ~$50B global beauty market.
Integration Roadmap — Estimated 24-Month Deployment
Phase 1: Technology Validation and Application Design
Duration: 6 months
This phase involves detailed validation of the drug release mechanism for target drugs and application sites, establishing basic device design and material selection. Technical collaboration with the National Institute for Materials Science will also be initiated.
Phase 2: Prototype Development and Performance Optimization
Duration: 9 months
Based on the foundational design, functional prototypes will be fabricated. Drug release volume, penetration depth, stability, and light irradiation conditions will be thoroughly evaluated to optimize performance and enhance reliability according to target market specifications.
Phase 3: Pre-clinical Evaluation and Manufacturing Process Establishment
Duration: 9 months
Safety and efficacy will be assessed through non-clinical trials, while establishing manufacturing processes and supply chains for mass production. Preparations for regulatory approval applications will proceed concurrently, paving the way for market introduction.
Technical Feasibility
This patent allows for the use of diverse, common materials for the light source (e.g., lasers, LEDs) and drug supply unit (e.g., porous materials, polymers, fiber aggregates, permeable/reverse osmosis membranes). This material flexibility, combined with high compatibility with existing electronics and medical device manufacturing techniques, suggests that adopting companies could minimize new capital expenditure, easily integrate into current manufacturing infrastructure, or adopt it as a module.
Success Scenario
Implementing this technology could enable more efficient and safer drug administration in clinical settings, minimizing patient stress. It is expected to improve treatment adherence, especially for pediatric and chronic disease patients, maximizing therapeutic efficacy. Furthermore, patients could safely and easily self-administer medication at home, significantly enhancing the quality of home healthcare.
Patent Record
APPLICATION NO.
特願2021-112466
REGISTRATION NO.
7656916
FILING DATE
2021/07/07
GRANT DATE
2025/03/27
EXPIRATION DATE
2041/07/07
PATENT HOLDER
国立研究開発法人物質・材料研究機構
Examination History
2024年03月14日
出願審査請求書
2024年11月26日
拒絶理由通知書
2024年12月12日
手続補正書（自発・内容）
2024年12月12日
意見書
2025年02月12日
拒絶理由通知書
2025年02月13日
意見書
2025年02月13日
手続補正書（自発・内容）
2025年03月05日
特許査定